Companies › Biothervax
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| rBCG-N-RSV Recombinant BCG vaccine expressing respiratory syncytial virus nucleoprotein to generate c | – | Phase 2 | Respiratory Syncytial Virus Infection Prevention | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07762014 | rBCG-N-RSV | Phase 2 | Respiratory Syncytial Virus Infection Prevention | Infectious disease | Sep 2027 |
No annotated target.
–
Shenzhen Shenxin Biotechnology OsteoRemedies Jiangsu ProteLight Pharmaceutical & Biotechnology Catalysis InventVacc Biologicals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.